Metformin facilitates osteogenic differentiation of bone marrow stromal cells through AMPK-dependent autophagy: an investigation into the healing of osteoporotic fractures in murine models

作者：Daolin Du, Shan Hong, Yanbin Zhang, Ziyu Wang, Hao Li, Zhicheng Gao · 发表于：Journal of Orthopaedic Surgery and Research · 年份：2025 · DOI：10.1186/s13018-025-06067-6 · 被引用次数：7 · 研究领域：Metabolism, Diabetes, and Cancer、Cancer-related Molecular Pathways、Autophagy in Disease and Therapy

Osteoporosis is a widespread metabolic bone disorder characterized by a reduction in bone density and structural deterioration, leading to an increased susceptibility to fractures. This study investigates the role of metformin (Met) in promoting the osteogenic differentiation of bone marrow stromal cells (BMSCs) through the activation of AMP-activated protein kinase (AMPK) and explores its potential application in the treatment of osteoporotic fractures. We conducted a series of in vivo and in vitro experiments to elucidate the mechanisms underlying the effects of metformin. In a murine model of osteoporosis, metformin treatment significantly enhanced tibia fracture healing, as evidenced by increased bone mineral density (BMD), bone volume fraction (BV/TV), trabecular number (Tb.N), and decreased trabecular separation (Tb.Sp), as observed through micro-computed tomography (Micro-CT) and histological analyses. Immunoblot and real-time PCR demonstrated that metformin upregulated collagen type I (Col-I), a key osteogenic marker, and osteoprotegerin (OPG), an inhibitor of osteoclast differentiation that contributes to bone homeostasis via activated the AMPK signaling pathway. In vitro, metformin enhanced the osteogenic differentiation of BMSCs, as indicated by elevated alkaline phosphatase (ALP) activity. Western blot and PCR analyses further revealed that metformin increased the expression of AMPK, phosphorylated AMPK (p-AMPK), mammalian target of rapamycin (mTOR), phosphorylate...